J4D Stock Overview
Operates as a consumer health company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
Kenvue Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.08 |
| 52 Week High | US$22.56 |
| 52 Week Low | US$16.08 |
| Beta | 0 |
| 11 Month Change | 4.84% |
| 3 Month Change | 15.82% |
| 1 Year Change | 18.71% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -11.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| J4D | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | 2.6% | -0.7% | -0.4% |
| 1Y | 18.7% | -8.4% | 7.1% |
Return vs Industry: J4D exceeded the German Personal Products industry which returned -8.4% over the past year.
Return vs Market: J4D exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| J4D volatility | |
|---|---|
| J4D Average Weekly Movement | 5.0% |
| Personal Products Industry Average Movement | 3.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: J4D has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: J4D's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 22,000 | Thibaut Mongon | www.kenvue.com |
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Kenvue Inc. Fundamentals Summary
| J4D fundamental statistics | |
|---|---|
| Market cap | €43.50b |
| Earnings (TTM) | €1.02b |
| Revenue (TTM) | €14.75b |
43.4x
P/E Ratio3.0x
P/S RatioIs J4D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J4D income statement (TTM) | |
|---|---|
| Revenue | US$15.46b |
| Cost of Revenue | US$6.51b |
| Gross Profit | US$8.95b |
| Other Expenses | US$7.89b |
| Earnings | US$1.06b |
Last Reported Earnings
Sep 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.55 |
| Gross Margin | 57.90% |
| Net Profit Margin | 6.88% |
| Debt/Equity Ratio | 80.7% |
How did J4D perform over the long term?
See historical performance and comparisonDividends
3.4%
Current Dividend Yield145%
Payout RatioDoes J4D pay a reliable dividends?
See J4D dividend history and benchmarks| Kenvue dividend dates | |
|---|---|
| Ex Dividend Date | Nov 13 2024 |
| Dividend Pay Date | Nov 27 2024 |
| Days until Ex dividend | 9 days |
| Days until Dividend pay date | 5 days |
Does J4D pay a reliable dividends?
See J4D dividend history and benchmarks